TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24292746

Group type: EXPERIMENTAL
Intervention: Herring diet (5 meals a week for 6 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference meat diet
Number of subjects: 32
Study: 23094808

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise program for six months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 68
Study: 20487485

Group type: EXPERIMENTAL
Intervention: Nurse-provided, community-based teaching of breast self-examination
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1510
Study: 17545893

Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Body mass model
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: CSA model
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 136
Study: 15708879

Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 682

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 682
Study: 12215237

Group type: EXPERIMENTAL
Intervention: Smoking intervention group
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Cotinine verification
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Carbon monoxide verification
Number of subjects: 5887
Study: 9795924

Group type: EXPERIMENTAL
Intervention: CIFN 9 micrograms, three times weekly for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIFN 15 micrograms, three times weekly for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN‐alpha‐2b 3 MU administered 3 times per week for 6 to 12 months
Number of subjects: 0
Study: 7614541

Group type: EXPERIMENTAL
Intervention: Voda guiding catheter (group 1, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Judkins or Amplatz guiding catheter (group 2, n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Voda guiding catheter (group 1)
Number of subjects: 100
Study: 2515571

Group type: EXPERIMENTAL
Intervention: ASA (3.0 g/day, in three divided doses) and misoprostol (600 mcg/day, co-administered with ASA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ASA and placebo
Number of subjects: 60
Study: 327003

Group type: EXPERIMENTAL
Intervention: Propoxyphene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of propoxyphene and acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31888977

Group type: EXPERIMENTAL
Intervention: Bluetooth beacon technology app activated
Number of subjects: 411

Group type: COMPARATOR
Intervention: Bluetooth beacon technology app not activated
Number of subjects: 411
Study: 31544290

Group type: EXPERIMENTAL
Intervention: Thulium fiber laser enucleation of the prostate
Number of subjects: 103

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate
Number of subjects: 103
Study: 30012981

Group type: EXPERIMENTAL
Intervention: NumTrey (locally produced fish-based RUTF)
Number of subjects: 121

Group type: COMPARATOR
Intervention: BP-100™ (imported milk-based RUTF)
Number of subjects: 121
Study: 26499270

Group type: EXPERIMENTAL
Intervention: PEG‐IFN/RBV
Number of subjects: 192

Group type: COMPARATOR
Intervention: PEG‐IFN alone
Number of subjects: 192

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 192
Study: 24138536

Group type: EXPERIMENTAL
Intervention: Saroglitazar 2 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 22030199

Group type: EXPERIMENTAL
Intervention: Lidocaine jet injection (0.2 mL of lidocaine 2%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Topical application of 1 mL of lidocaine gel 2% (control)
Number of subjects: 42
Study: 19606510

Group type: EXPERIMENTAL
Intervention: Seven‐star Needle Stimulation (30 sessions over 6 weeks, 5 to 10 min per session)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (waiting list, no treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Seven‐star Needle Stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 17260315

Group type: EXPERIMENTAL
Intervention: Blue light filter IOLs (AF‐1 UY, Hoya, Japan)
Number of subjects: 43

Group type: COMPARATOR
Intervention: IOLs without blue light filter (AF‐1 UV, Hoya, Japan)
Number of subjects: 43
Study: 15029476

Group type: EXPERIMENTAL
Intervention: New pharmacological substances for metaphylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established dietary advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Good common practice drugs
Number of subjects: 0
Study: 11438057

Group type: EXPERIMENTAL
Intervention: Diode laser photocoagulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 10
Study: 9504953

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified liquid milk (500 ml per day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Unfortified milk (control group)
Number of subjects: 51
Study: 7988193

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide, 800 micrograms
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2563787

Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (supine level without ischaemia)
Number of subjects: 30
Study: 30899086

Group type: EXPERIMENTAL
Intervention: Molecular apocrine (MA) subtype patients receiving neoadjuvant chemotherapy
Number of subjects: 846

Group type: COMPARATOR
Intervention: Triple-negative (TN) basal-like tumours
Number of subjects: 846
Study: 28027226

Group type: EXPERIMENTAL
Intervention: Wedge resection of the bony nasal pyramid from the base of the nasal bone
Number of subjects: 166

Group type: COMPARATOR
Intervention: Oblique hump resection
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Base nasal bone resection
Number of subjects: 166

Group type: COMPARATOR
Intervention: Different plastic surgeons' evaluations
Number of subjects: 166
Study: 25890572

Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 24374800

Group type: EXPERIMENTAL
Intervention: TACE combined with endovascular implantation of an iodine-125 seed strand
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional TACE
Number of subjects: 85
Study: 22947546

Group type: EXPERIMENTAL
Intervention: Galileo platform (GP) at 22 Hz
Number of subjects: 10

Group type: COMPARATOR
Intervention: Juvent1000 platform (JP)
Number of subjects: 10
Study: 19848196

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI), 60 mL once a day for 10 days each month over a treatment course of 6 months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment alone (Control group).
Number of subjects: 100
Study: 17720642

Group type: EXPERIMENTAL
Intervention: Subcutaneous drains
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no drains)
Number of subjects: 250
Study: 15750884

Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 intraocular lens
Number of subjects: 64

Group type: COMPARATOR
Intervention: Acrysof SA60AT intraocular lens
Number of subjects: 64
Study: 11968069

Group type: EXPERIMENTAL
Intervention: Extended release formulations of metoprolol (100 mg) with varying release rates (slow, moderate, fast)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral solution of metoprolol (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended release formulations of metoprolol (100 mg) with fast input
Number of subjects: 0
Study: 10365008

Group type: EXPERIMENTAL
Intervention: GR205171 25 mg i.v.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7735677

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 23
Study: 1774544

Group type: EXPERIMENTAL
Intervention: Vitamin C administration (3 grams per day during Weeks 5 to 8)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Temporal delays imposed between successive responses during sequence acquisition
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control condition with reinstated stimuli correlated with sequence position
Number of subjects: 13
Study: 6814610

Group type: EXPERIMENTAL
Intervention: Counselling (supported) group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Contrast group (routine hospital care)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Socially isolated women and those with lack of intimacy in marital relations
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unsupported group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Support and counselling
Number of subjects: 50
Study: 30502933

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28297698

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (365 mg of oral magnesium once daily for 3 months)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (once daily for 3 months)
Number of subjects: 128
Study: 25028997

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 21
Study: 23915235

Group type: EXPERIMENTAL
Intervention: Butterfly Girls online program (8-episode animated, interactive comic)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 390
Study: 20156926

Group type: EXPERIMENTAL
Intervention: TPA023B (1.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPA023B (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRK‐409
Number of subjects: 0
Study: 18078789

Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control garment (usual netball attire)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo garment
Number of subjects: 0
Study: 17171429

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate 12.5 mg/day (increased to tolerable maximal dose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both groups (Carvedilol and Metoprolol)
Number of subjects: 33
Study: 15765005

Group type: EXPERIMENTAL
Intervention: Computerized training of repeated reading of a limited set of 32 training words over a period of up to 25 days
Number of subjects: 20
Study: 11572290

Group type: EXPERIMENTAL
Intervention: OptiBond Solo (OS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (PB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Syntac Single Component (SSC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: OptiBond Solo (OS) and Prime & Bond 2.1 (PB)
Number of subjects: 15
Study: 9773836

Group type: EXPERIMENTAL
Intervention: Experimental formula with egg phospholipids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 0
Study: 7947595

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 8
Study: 3415546

Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29415258

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1-4 mg/d
Number of subjects: 1072
Study: 27530473

Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich purple sweet potato beverage (PSP), 177 mg anthocyanins per 125-ml bottle, 3 bottles per day for 8 weeks
Number of subjects: 40
Study: 25069476

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with drug reactions (rs1799929 and rs1495741 in NAT2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with thromboembolism (rs7294, rs9923231 and rs9934438 in VKORC1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with HIV/AIDS and solid tumors (rs2242046 in SLC28A1)
Number of subjects: 120
Study: 22981685

Group type: EXPERIMENTAL
Intervention: Droperidol (5 mg)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 336
Study: 21917777

Group type: EXPERIMENTAL
Intervention: Responsive cortical stimulation (treatment)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 191
Study: 19805747

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Antioxidant
Number of subjects: 26
Study: 16671482

Group type: EXPERIMENTAL
Intervention: Aesculap-Miethke GA-Valve (GAV; counterbalancer)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Aesculap-Miethke Dualswitch-Valve (DSV; switcher)
Number of subjects: 54
Study: 15724775

Group type: EXPERIMENTAL
Intervention: Standard behavioral counseling (N=22)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Culturally sensitive counseling (N=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physician advice (N=10)
Number of subjects: 60
Study: 11378006

Group type: EXPERIMENTAL
Intervention: Metoprolol (50, 100, and 200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carvedilol (25, 50, and 100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9223201

Group type: EXPERIMENTAL
Intervention: 30 mL 0.5% bupivacaine with 1:200,000 epinephrine and 1 mg preservative-free morphine (group BUP-MORPH)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 30 mL 0.5% bupivacaine with 1:200,000 epinephrine (group BUP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 30 mL normal saline with 1:200,000 epinephrine and 1 mg preservative-free morphine (group MORPH)
Number of subjects: 75
Study: 7954233

Group type: EXPERIMENTAL
Intervention: Temporary hepatic artery occlusion followed by intraportal infusion of 5‐fluorouracil (5‐FU) and oral allopurinol
Number of subjects: 60

Group type: COMPARATOR
Intervention: No regional or systemic treatment
Number of subjects: 60
Study: 2928654

Group type: EXPERIMENTAL
Intervention: Tampon use
Number of subjects: 35

Group type: COMPARATOR
Intervention: Napkin use
Number of subjects: 35
Study: 31724966

Group type: EXPERIMENTAL
Intervention: semaglutide 2 mg/1.5 ml (1.34 mg/ml) prefilled pen for subcutaneous injection
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo 1.5 ml, pen-injector for subcutaneous injection
Number of subjects: 140
Study: 28403291

Group type: EXPERIMENTAL
Intervention: Home visits with instructions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 32
Study: 26163740

Group type: EXPERIMENTAL
Intervention: Closed suctioning system
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open suctioning system
Number of subjects: 42
Study: 23265328

Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII) LVAD support
Number of subjects: 1122
Study: 21789679

Group type: EXPERIMENTAL
Intervention: Harmonic Focus™ (HF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Knot tying (KT)
Number of subjects: 81
Study: 18679148

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) plus standard therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 50
Study: 16702897

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 15381054

Group type: EXPERIMENTAL
Intervention: Aggrenox (2 pills/daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin (81 mg plus matching placebo/daily)
Number of subjects: 40
Study: 11183453

Group type: EXPERIMENTAL
Intervention: Clindamycin ovule (3-day treatment)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Metronidazole vaginal gel
Number of subjects: 96
Study: 8752295

Group type: EXPERIMENTAL
Intervention: Bovine rotavirus vaccines
Number of subjects: 5353

Group type: EXPERIMENTAL
Intervention: RRV-based vaccines
Number of subjects: 5353

Group type: EXPERIMENTAL
Intervention: M37 vaccine
Number of subjects: 5353

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 5353

Group type: EXPERIMENTAL
Intervention: All vaccines with demonstrable immunogenicity
Number of subjects: 5353
Study: 1371211

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus intravenous cyclophosphamide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 26
Study: 6827127

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 19
Study: 29908826

Group type: EXPERIMENTAL
Intervention: Intramyocardial CD34+ cell therapy (5 × 10^4 to 5 × 10^5 cells/kg)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 28684776

Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation therapy (CCRT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 27
Study: 25889698

Group type: EXPERIMENTAL
Intervention: Mepivacaine 3%
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Articaine 4%
Number of subjects: 31
Study: 24687582

Group type: EXPERIMENTAL
Intervention: 12 weeks of aerobic training on a cycle ergometer
Number of subjects: 23
Study: 22808616

Group type: EXPERIMENTAL
Intervention: Intravenous catheter-guided laser ablation (ICLA)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Stab avulsion (SA)
Number of subjects: 134
Study: 19328438

Group type: EXPERIMENTAL
Intervention: Omega 3 alone
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Multidomain intervention alone
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Omega 3 plus multidomain intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 17352269

Group type: EXPERIMENTAL
Intervention: Lipoplatin/5-FU
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cisplatin/5-FU
Number of subjects: 12
Study: 15200199

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (4mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 11473220

Group type: EXPERIMENTAL
Intervention: Self-reported STD status
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Accurate reporting of positive STD status
Number of subjects: 522
Study: 9916605

Group type: EXPERIMENTAL
Intervention: Valsartan 10 mg
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Valsartan 20 mg
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 4067

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 4067

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4067
Study: 8066849

Group type: EXPERIMENTAL
Intervention: Follow-up home visits by a district nurse and general practitioner
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual discharge procedures
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Follow-up home visits
Number of subjects: 344
Study: 3195836

Group type: EXPERIMENTAL
Intervention: Oral prednisone (20 mg 3 times a day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29472265

Group type: COMPARATOR
Intervention: Oral vitamin B12 supplementation (at least two recommended dietary allowances daily for at least 6 months)
Number of subjects: 0
Study: 31416769

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg three times daily)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 147
Study: 28646893

Group type: EXPERIMENTAL
Intervention: Cobimetinib and vemurafenib
Number of subjects: 493

Group type: COMPARATOR
Intervention: Vemurafenib
Number of subjects: 493
Study: 25123377

Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 6
Study: 23623342

Group type: EXPERIMENTAL
Intervention: Carto‐Sound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electro-anatomic mapping (EAM)
Number of subjects: 60
Study: 22137134

Group type: EXPERIMENTAL
Intervention: Anatomic location of primary melanoma (head/neck, trunk, upper extremity, lower extremity)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analysis of anatomic location
Number of subjects: 2500
Study: 19224292

Group type: EXPERIMENTAL
Intervention: Modified Roux‐en‐Y gastrojejunostomy reconstruction with jejunostomy feeding tube
Number of subjects: 247

Group type: COMPARATOR
Intervention: Conventional gastric bypass (control group)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Comparison of modified group vs control group
Number of subjects: 247
Study: 16686550

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 9
Study: 12874531

Group type: EXPERIMENTAL
Intervention: Capsaicin (50 mg of powder of red pepper with 0.25% of capsaicin)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (empty capsules)
Number of subjects: 84
Study: 10919900

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% four times daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: Artificial tears four times daily
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5%
Number of subjects: 117

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 117
Study: 9004191

Group type: EXPERIMENTAL
Intervention: Extended-release experimental formulations (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inderal LA (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inderal immediate-release dosage form (2 x 40 mg)
Number of subjects: 0
Study: 1359318

Group type: EXPERIMENTAL
Intervention: Oral artemether at 700 mg total dose over 5 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mefloquine 1250 mg in divided doses
Number of subjects: 46